The imaging systems that combine tomography with radionuclide tracers are PET (positron emission tomography) and SPECT (single-photon emission computed tomography). Both work by injecting a small amount of a radioactive substance into the body, then capturing the radiation it emits to build a three-dimensional picture of how organs and tissues are functioning. While conventional imaging like X-rays and CT scans show anatomy, PET and SPECT reveal what’s actually happening at the cellular level, such as how actively a tissue is using energy or how well blood is flowing.
How PET Imaging Works
PET relies on tracers labeled with isotopes that emit positrons, which are the antimatter counterpart of electrons. Once injected, the tracer travels through the body and concentrates in areas with high metabolic activity. As the isotope decays, each positron it releases almost immediately collides with a nearby electron. That collision, called annihilation, produces two high-energy photons that fly off in opposite directions.
A ring of detectors surrounding the patient picks up both photons nearly simultaneously. When two detectors register a hit within an extremely narrow time window, the system records it as a valid event and draws a line between those two points. Millions of these lines are collected and fed into a reconstruction algorithm that maps out exactly where in the body the tracer accumulated. This “electronic collimation” eliminates the need for a physical filter between the patient and the detector, giving PET a sensitivity advantage: typical systems capture 1 to 5% of all emitted radiation, which sounds low but is significantly higher than SPECT’s collection rate.
How SPECT Imaging Works
SPECT uses tracers that emit single gamma rays rather than pairs of photons. Because there’s no partner photon to help pinpoint the source, SPECT needs a physical device called a collimator, essentially a lead plate with tiny holes, mounted on a gamma camera. The collimator blocks gamma rays arriving at steep angles and only lets through those traveling in a known direction, which tells the system where each photon originated.
The gamma camera rotates around the patient, capturing images from many angles. A computer then reconstructs those flat projections into a full 3D map of tracer distribution, much like a CT scanner builds cross-sections from X-ray projections. The tradeoff for this design is sensitivity. Clinical SPECT systems detect a very small fraction of the gamma rays the tracer emits, often less than 0.1%, because the collimator blocks most photons to preserve image clarity. Advanced systems can achieve sub-millimeter spatial resolution, but only by sacrificing even more sensitivity.
Radionuclides Used in Each System
The two systems use fundamentally different types of radioactive isotopes. PET tracers rely on positron emitters with short half-lives. The most widely used is fluorine-18, which has a half-life of about 110 minutes, long enough to manufacture the tracer and complete a scan. Carbon-11, with a half-life of roughly 20 minutes, is used in research settings but requires an on-site cyclotron to produce.
SPECT tracers use gamma-emitting isotopes with generally longer half-lives. Technetium-99m is by far the most common. It emits pure gamma radiation with a half-life of 6 hours, making it practical for a wide range of diagnostic tests. Other SPECT isotopes include iodine-123, xenon-133, thallium-201, and indium-111, each chosen for how it behaves in specific organs or biological pathways.
What PET Is Used For
PET’s biggest role is in cancer care. Most cancers consume glucose at a much higher rate than normal tissue because tumor cells overexpress glucose transporters and ramp up their energy-producing enzymes. The standard PET tracer, a radioactive glucose analog called FDG, exploits this. It gets taken up by hungry cancer cells and trapped inside, lighting up tumors on the scan. FDG-PET is now considered indispensable for staging known cancers, spotting hidden metastases that other imaging misses, and evaluating whether chemotherapy, immunotherapy, or radiation is working. Response criteria specific to PET (called PERCIST) assess changes in metabolic activity rather than just tumor size, catching treatment effects earlier than anatomy-based measurements can.
PET also has applications in neurology, where it can map brain metabolism in conditions like Alzheimer’s disease, and in cardiology, where it assesses blood flow and tissue viability in the heart muscle.
What SPECT Is Used For
SPECT’s most established application is in cardiology. A myocardial perfusion scan, one of the most commonly ordered nuclear medicine tests, uses SPECT to evaluate blood flow to the heart. The tracer is absorbed by healthy heart muscle, so areas with poor blood supply show up as “cold spots” on the image. Doctors use these scans to diagnose coronary artery disease, evaluate new or ongoing chest pain, assess damage after a heart attack, and check whether blood flow has improved after bypass surgery, angioplasty, or stent placement.
SPECT is also used in neurology to image blood flow patterns in the brain, which can help with evaluating epilepsy and certain types of dementia. Its lower cost and wider availability compared to PET make it a practical choice for many clinical settings.
Hybrid Systems: PET/CT and PET/MRI
Neither PET nor SPECT produces detailed anatomical images on its own. The functional information is rich, but pinpointing exactly where in the body a hot spot sits can be difficult without a structural reference. This led to the development of hybrid scanners that combine radionuclide imaging with anatomical imaging in a single machine.
PET/CT is now the standard configuration for oncological PET. The CT component provides a precise anatomical map, and the PET component overlays metabolic data on top of it. Combined PET/CT has proven more diagnostically valuable than either PET or CT performed separately. PET/MRI is a newer option that pairs PET with magnetic resonance imaging. MRI offers superior soft-tissue contrast compared to CT and can itself provide functional data like diffusion and perfusion imaging. This combination is particularly useful for cancer treatment planning and monitoring.
Radiation Exposure
Both PET and SPECT involve exposure to ionizing radiation from the injected tracer. For a standard whole-body FDG-PET/CT scan, the average effective dose is roughly 17.6 millisieverts (mSv), with the CT portion contributing a significant share. Early PET/CT protocols delivered around 25 mSv, but dose-reduction techniques have brought that down. PET/MRI cuts exposure dramatically, averaging about 3.6 mSv, because MRI uses magnetic fields rather than X-rays for its anatomical images, representing roughly an 80% dose reduction compared to standard PET/CT.
For context, a single chest X-ray delivers around 0.02 mSv, and a standard CT scan of the chest delivers roughly 7 mSv. The tracer itself typically contributes several mSv to the total dose. For patients who need repeated scans to monitor treatment over months or years, cumulative radiation is a real consideration, and choosing lower-dose protocols or PET/MRI when available can make a meaningful difference.